Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has initiated a cash tender offer to acquire all outstanding common shares of Antares Pharma, Inc. (NASDAQ: ATRS) for $5.60 per share. The offer follows the Merger Agreement dated April 12, 2022, and is set to expire on May 23, 2022, unless extended. Conditions for closing include the tender of a majority of Antares shares and compliance with regulatory approvals. Antares' Board of Directors recommends stockholders accept the offer. The transaction aims to enhance Halozyme's position in the biopharmaceutical market.
Halozyme Therapeutics is set to acquire Antares Pharma for $5.60 per share, valuing the transaction at approximately $960 million. This acquisition aims to enhance Halozyme's drug delivery business and diversify its revenue streams through Antares' auto injector platform. The deal is anticipated to be immediately accretive to Halozyme's revenue and non-GAAP earnings in 2022, with significant growth projections into 2027. The merger is backed by both companies' boards and expected to close in the first half of 2022.
Halozyme Therapeutics (NASDAQ: HALO) announced a global collaboration with Chugai Pharmaceutical for the use of its ENHANZE® drug delivery technology. Chugai will pay an upfront fee of $25 million and potential future payments totaling up to $160 million based on specific milestones. This agreement marks Halozyme's twelfth collaboration involving over 60 therapeutic targets and aims to enhance patient treatment options through subcutaneous injections. Halozyme will also benefit from royalties on sales of products utilizing this technology.
The recent Phase 3 ADAPT-SC study results demonstrate that subcutaneously administered efgartigimod shows noninferior total IgG reduction at day 29 compared to intravenous administration, a significant milestone for Halozyme (NASDAQ: HALO). This achievement positions the treatment for generalized myasthenia gravis (gMG) favorably, paving the way for argenx to submit a Biologics License Application (BLA) to the FDA by the end of 2022. The success underscores the effectiveness of Halozyme's ENHANZE® technology in enhancing drug delivery options.
Halozyme Therapeutics (NASDAQ: HALO) has appointed Moni Miyashita to its board of directors, bringing over 25 years of experience in corporate strategy, mergers & acquisitions, and business transformation. The CEO, Dr. Helen Torley, expressed excitement over Miyashita's expertise, which aligns with the company's goal to expand growth opportunities. Miyashita, previously with Valo Health and IBM, aims to leverage her experience to enhance Halozyme's strategic initiatives. Halozyme is recognized for its ENHANZE® technology, improving treatment experiences for patients globally.
Halozyme Therapeutics reported robust financial results for Q4 and full year 2021, with total revenue hitting $443.3 million, a 66% increase Year-over-Year (YoY). Royalty revenue soared 130% YoY, driven mainly by the subcutaneous products DARZALEX® and Phesgo®. The company anticipates a further 50% growth in royalty revenue in 2022. Although Q4 revenue dropped to $102.0 million from $121.7 million in 2020, net income for the full year totaled $402.7 million, or $2.74 per share. Halozyme's guidance for 2022 projects revenues of $530-560 million, with a net income of $270-295 million.
Halozyme Therapeutics (NASDAQ: HALO) has announced it will host a webcast for its fourth quarter 2021 financial results on February 22, 2022, at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of financial results after market close. Halozyme emphasizes its innovative ENHANZE® technology, which has improved treatment times for over 500,000 patients globally across five products. The company partners with major biopharmaceutical companies, generating revenue through collaborations and royalties.
Halozyme Therapeutics (NASDAQ: HALO) has promoted Nicole LaBrosse to Chief Financial Officer (CFO), succeeding Elaine Sun, who is leaving for another opportunity. LaBrosse, with over 18 years of experience, joined Halozyme in 2015 and has held progressively responsible roles, including Vice President of Finance since 2020. CEO Helen Torley expressed confidence in LaBrosse's ability to support the company's growth. Halozyme aims to improve patient experiences through its ENHANZE® technology, which streamlines treatment delivery, impacting over 500,000 patients globally.
Halozyme Therapeutics (NASDAQ: HALO) has announced its financial guidance for 2022, projecting total revenue between $530 million and $560 million, a growth of 23-26% from 2021. Royalties from products utilizing ENHANZE technology are expected to reach $300 million, a 50% increase. Operating income is forecasted at $350 million to $380 million, with a margin exceeding 65%. Key initiatives include further product development and share repurchase plans totaling up to $250 million.
Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on January 10, 2022, at 7:30 a.m. PT. The conference runs from January 10-13, 2022. Interested parties can access the presentation via the Investors section of Halozyme's website. Halozyme specializes in biopharmaceutical solutions, particularly its ENHANZE® technology, which enhances drug delivery efficiency and has reached over 500,000 patients globally.